Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
ImmuneID is a precision immunology company that provides a technological platform to deliver insights into the human immune response.
Renovia was a developer of prescription digital therapeutics for pelvic floor disorders. Renovia ceased operations in late 2022.
Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases.
ArcherDX is a biotechnology firm specializing in cancer research.
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.
Recros Medica is a medical device company developing technologies to treat skin laxity and focal aesthetic contour deformities.
Flex Pharma develops clinically proven products and treatments for muscle cramps and spasms.
Longwood Fund has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Longwood Fund's top investment sectors include Biotechnology, Life Science, Therapeutics, Health Care, Medical. The firm invests across 13 different industry categories.
Among tracked funding rounds, Rectify Pharmaceuticals received $100.0M in a Series A round. Longwood Fund's total known invested capital is $5.2B.
Longwood Fund's average investment size is $80.6M across its portfolio of 56 companies.
Recent Longwood Fund portfolio additions include Rectify Pharmaceuticals, ImmuneID, Renovia, Millendo Therapeutics. These companies were founded in 2020 or later.